About 30 results found for searched term "Ras" (0.006 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1663 | AZD1152-HQPA | Aurora Kinase |
| Barasertib | ||
| AZD1152-HQPA (Barasertib) is a highly potent and selective inhibitor of Aurora with Ki values of 0.36 and 1369 nM for Aurora B and Aurora A respectively. | ||
| M1754 | WP1130 | JAK |
| Degrasyn | ||
| Degrasyn (WP1130) is a small molecular deubiquitinase (DUB) inhibitor and suppresses JAK-Stat signaling pathway. | ||
| M1895 | Prasugrel hydrochloride | P2 Receptor |
| Prasugrel hydrochloride is a novel inhibitor of platelet activation and aggregation. | ||
| M2234 | Prasugrel | P2 Receptor |
| Effient, Efient | ||
| Prasugrel is a platelet inhibitor irreversibly binding to P2Y12 receptors. | ||
| M2364 | ABT-348 | Aurora Kinase |
| Ilorasertib | ||
| ABT-348 is a novel ATP-competitive inhibitor of Aurora B, Aurora C and Aurora A with IC50 of 7 nM, 1 nM and 120 nM, respectively. | ||
| M2602 | Hydrastinine hydrochloride | Others |
| Hydrastinine hydrochloride is a semisynthetic alkaloid from the hydrolysis of the alkaloid hydrastine, which was found naturally in small quantities in Hydrastis canadensis L. | ||
| M2606 | Tirasemtiv | Others |
| CK-2017357 | ||
| Tirasemtiv is a a small-molecule fast-skeletal-troponin activator, which is being developed as a potential treatment for diseases and conditions associated with aging, muscle weakness and wasting or neuromuscular dysfunction. | ||
| M2679 | Erastin | Ferroptosis |
| Erastin is a ferroptosis activator by acting on mitochondrial VDAC, exhibiting selectivity for tumor cells bearing oncogenic RAS. *The compound is unstable in solutions, freshly prepared is recommended | ||
| M2825 | Lurasidone hydrochloride | 5-HT Receptor |
| SM-13496 | ||
| Lurasidone is an atypical antipsychotic, inhibits Dopamine D2, 5-HT2A, 5-HT7, 5-HT1A and noradrenaline α2C with IC50 of 1.68 nM, 2.03 nM, 0.495 nM, 6.75 nM and 10.8 nM, respectively. | ||
| M2878 | Nexturastat A | HDAC |
| Nexturastat A is a potent and selective HDAC6 inhibitor with IC50 of 5 nM, >190-fold selectivity over other HDACs. | ||
| M2954 | PPADS Tetrasodium Salt | P2 Receptor |
| PPADS tetrasodium salt is a non-selective P2 purinergic antagonist blocking recombinant P2X1, P2X2, P2X3, P2X5 with IC50 of 1-2.6 μM, native P2Y2-like with IC50 of ~ 0.9 mM, and recombinant P2Y4 receptors with IC50 of ~ 15 mM | ||
| M3008 | SGI-1027 | DNA Methyltransferase |
| DNA Methyltransferase Inhibitor II | ||
| SGI-1027 is a DNMT inhibitor with IC50 of 6, 8, 7.5 μM for DNMT1, DNMT3A, and DNMT3B | ||
| M3257 | Torsemide | Others |
| Torasemide | ||
| Torsemide is a pyridine-sulfonyl urea type loop diuretic with an IC50 of 2.7 ± 0.17 μM. | ||
| M3361 | Rasagiline Mesylate | Monoamine Oxidase |
| TVP-1012 | ||
| Rasagiline Mesylate is a new MAO-B inhibitor for the treatment of idiopathic Parkinson's disease. | ||
| M3394 | Deltarasin | PDE |
| Deltarasin is a novel small molecule which inhibits the KRAS-PDEδ interaction and thus impairing oncogenic KRAS signalling. | ||
| M3663 | K-Ras(G12C) inhibitor 9 | Ras |
| K-Ras(G12C) inhibitor 9 is an allosteric inhibitor of oncogenic K-Ras(G12C). | ||
| M3756 | Oncrasin-1 | DNA/RNA Synthesis |
| Oncrasin-1 is a small molecule RNA polymerase II inhibitor that kills various human lung cancer cells with K-Ras mutations at low or submicromolar concentrations. | ||
| M3803 | Sotrastaurin | PKC |
| AEB071 | ||
| Sotrastaurin is a potent and orally-active pan-PKC inhibitor, with Kis of 0.22 nM, 0.64nM, 0.95 nM, 1.8 nM, 2.1 nM and 3.2 nM for PKCθ, PKCβ, PKCα, PKCη, PKCδ and PKCε, respectively. | ||
| M3885 | 6H05 trifluoroacetate | Ras |
| K-Ras inhibitor | ||
| 6H05 is a selective and allosteric inhibitor of oncogenic K-Ras(G12C). | ||
| M4030 | Crassicauline-A | Others |
| Crassicaulin A | ||
| Crassicauline A (Crassicaulin A) is A bioactive alkaloid in aconite roots. Crassicauline A (Crassicaulin A) had antifeedant activity against the adult Raptor, and its EC50 value was 1134.5 PPM. | ||
| M4038 | Astragaloside-I | Wnt/beta-catenin |
| Astrasieversianin IV; Cyclosieversioside B | ||
| Astragaloside I is a natural compound isolated from astragalus. Astragaloside I has osteogenic activity by stimulating osteoblast differentiation through the Wnt/β-catenin signaling pathway. | ||
| M4039 | Astragaloside-II | Others |
| Astrasieversianin VIII | ||
| Astragaloside II is a natural compound isolated from Astragalus membranaceus. | ||
| M4042 | Isoastragaloside-II | Others |
| Astrasieversianin-VII | ||
| Isoastragaloside II, a kind of astragaloside IV, was isolated from the hairy roots of Astragalus membranaceus. | ||
| M4203 | Epimedin-A1 | Others |
| Hexandraside F | ||
| Epimedin A1 is a flavonoid extracted from epimedium. | ||
| M4644 | Dryocrassin-ABBA | Anti-infection |
| Dryocrassin ABBA (Dryocrassin) is a natural product of flavonoids extracted from Sophora flavescens, with antiviral and antibacterial activities. Dryocrassin ABBA has antiviral activity against H5N1 avian influenza virus. Dryocrassin ABBA could inhibit coagulase activity of STaphylococcus aureus vWbp. Dryocrassin ABBA can inhibit the immune stimulation of dendritic cells and prolong the survival rate of allografts. | ||
| M4703 | Lupeol | Androgen Receptor |
| Clerodol; Monogynol B; Fagarasterol | ||
| Lupeol (Clerodol; Monogynol B; Fagarasterol (Fagarasterol) is an active pentacyclic triterpenoid with antioxidant, anti-tumor and anti-inflammatory activities. Lupeol is a potent androgen receptor inhibitor that can be used in cancer research, especially in prostate cancer with androgen-dependent phenotypes (ADPC) and castration-resistant phenotypes (CRPC). | ||
| M5946 | Salirasib | Ras |
| S-Farnesylthiosalicylic acid; Farnesyl Thiosalicylic Acid; FTS | ||
| Salirasib is a potent competitive prenylated protein methyltransferase (PPMTase) inhibitor with Ki of 2.6 μM, which inhibits Ras methylation. Phase 2. | ||
| M4881 | Actinomycin D | DNA/RNA Synthesis |
| Actinomycin Aiv; Dactinomycin; Act D; RASP-101 | ||
| Actinomycin d is a bright red rhomboid prisms or red powder. | ||
| M4898 | Histone Acetyltransferase Inhibitor II | Histone Acetyltransferase |
| Histone Acetyltransferase Inhibitor II, insulin producing cells capable of secreting blood glucose regulating hormones, specially insulin, in response to physiological signals, method of production of said cells and uses thereof. | ||
| M5557 | Deferasirox | Cytochrome P450 (e.g. CYP17) |
| CGP-72670, ICL-670 | ||
| Deferasirox (ICL-670) is an iron chelator that causes iron loss that promotes BclxL downregulation and cell death. Deferasirox (ICL-670) also induced P450 3A4 and inhibited 2C8 and 1A2. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
